LivaNova Raises Full-Year Guidance on Strong Q2 Performance
Event summary
- LivaNova reported Q2 2026 revenue of $390.6 million, up 10.8% year-over-year.
- The company raised full-year 2026 revenue guidance to 8-9% growth from 7-8%.
- Adjusted diluted EPS guidance increased by $0.10 at the midpoint to $4.30-$4.40.
- LivaNova secured a long-term agreement with Thermo Fisher Scientific for critical oxygenator components.
- The company recognized an €81.8 million ($95.4 million) tax benefit from the Italian authority.
The big picture
LivaNova's strong Q2 results and raised guidance reflect sustained performance in its Cardiopulmonary and Epilepsy businesses. The strategic partnership with Thermo Fisher Scientific underscores the company's focus on securing critical supply chain components amid industry-wide challenges. The favorable tax ruling further strengthens LivaNova's financial position, positioning it for long-term value creation.
What we're watching
- Supply Chain Stability
- How the Thermo Fisher Scientific agreement will impact LivaNova's oxygenator output and customer demand satisfaction.
- Financial Flexibility
- Whether the reduced adjusted free cash flow guidance reflects strategic investments or operational challenges.
- Regulatory Tailwinds
- The pace at which favorable tax rulings could boost LivaNova's financial performance in key markets.
Related topics